Im­muno­vant shares mid-stage Graves’ dis­ease da­ta; FDA lifts Re­zo­lute’s hold

Plus, news about Xen­cor, Bam­busa Ther­a­peu­tics, Grin Ther­a­peu­tics and Vax­cyte:

Im­muno­vant re­ports Phase 2a Graves’ dis­ease da­ta: Pa­tients tak­ing ba­to­climab for 12 weeks saw a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER